143:@0.890196:0.957873:0.914828:0.957873:0.914828:0.938882:0.890196:0.938882:0.007450:0.008591:0.008591
5:@0.941813:0.435294:0.963291:0.435294:0.963291:0.387816:0.941813:0.387816:0.021478
OPTIMIZING NANOPORE SEQUENCING-BASED DETECTION OF STRUCTURAL VARIANTS ENABLES:@0.340931:0.057372:0.882352:0.057372:0.882352:0.040253:0.340931:0.040253:0.008442:0.007975:0.006387:0.003511:0.011112:0.003511:0.006630:0.003511:0.008759:0.008404:0.002988:0.008759:0.007919:0.008759:0.008442:0.008050:0.008442:0.008423:0.006985:0.002988:0.007807:0.006985:0.008442:0.008367:0.006985:0.008759:0.008255:0.003511:0.008759:0.008404:0.005155:0.008121:0.007713:0.007807:0.006985:0.008423:0.002988:0.008423:0.006985:0.006387:0.006985:0.008178:0.006387:0.003511:0.008442:0.008759:0.002988:0.008442:0.006593:0.002988:0.007732:0.006387:0.008367:0.008367:0.008180:0.006387:0.008367:0.008423:0.007919:0.006292:0.002801:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.006313:0.007807:0.002988:0.006985:0.008759:0.007919:0.008236:0.006481:0.006871:0.007807
INDIVIDUALIZED CIRCULATING TUMOR DNA-BASED DISEASE MONITORING IN CANCER PATIENTS:@0.337347:0.073247:0.882352:0.073247:0.882352:0.056128:0.337347:0.056128:0.003511:0.008759:0.008423:0.003511:0.007620:0.003511:0.008423:0.008253:0.007919:0.006481:0.003511:0.006630:0.006985:0.008423:0.002988:0.008255:0.003511:0.008309:0.008255:0.008367:0.006481:0.007097:0.006387:0.003511:0.008759:0.008404:0.002988:0.006387:0.008367:0.011112:0.008442:0.008423:0.002988:0.008423:0.008759:0.007543:0.005155:0.008124:0.007713:0.007807:0.006985:0.008423:0.002988:0.008423:0.003511:0.007807:0.006985:0.007713:0.007807:0.006985:0.002988:0.011112:0.008442:0.008759:0.003511:0.006311:0.008442:0.008423:0.003511:0.008759:0.008404:0.002988:0.003511:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.007581:0.007099:0.006387:0.003511:0.006985:0.008759:0.006311:0.007807
Pros1:@0.210922:0.279910:0.254822:0.279910:0.254822:0.263521:0.210922:0.263521:0.009888:0.006074:0.010520:0.007588:0.009830
Pros4:@0.281194:0.279910:0.325096:0.279910:0.325096:0.263521:0.281194:0.263521:0.009888:0.006076:0.010520:0.007588:0.009830
Pros5:@0.351466:0.279910:0.395366:0.279910:0.395366:0.263521:0.351466:0.263521:0.009888:0.006074:0.010520:0.007588:0.009830
Pros6:@0.421736:0.279910:0.465636:0.279910:0.465636:0.263521:0.421736:0.263521:0.009886:0.006076:0.010520:0.007588:0.009830
100:@0.163400:0.135675:0.187975:0.135675:0.187975:0.122017:0.163400:0.122017:0.008192:0.008192:0.008192
10:@0.171128:0.167762:0.187512:0.167762:0.187512:0.154104:0.171128:0.154104:0.008192:0.008192
1:@0.178873:0.201043:0.187065:0.201043:0.187065:0.187385:0.178873:0.187385:0.008192
0.1:@0.168015:0.234324:0.187703:0.234324:0.187703:0.220666:0.168015:0.220666:0.008192:0.003305:0.008192
0.01:@0.160270:0.267605:0.188151:0.267605:0.188151:0.253947:0.160270:0.253947:0.008192:0.003305:0.008192:0.008192
VAF (%) :@0.173546:0.220041:0.173546:0.173899:0.150514:0.173899:0.150514:0.220041:0.009646:-0.937218:0.000000:0.000000:0.000000:0.000000:0.000000:0.992714
SV-A at baseline:@0.525417:0.203368:0.653053:0.203368:0.653053:0.186979:0.525417:0.186979:0.009437:0.010422:0.005873:0.011717:0.004062:0.009226:0.006333:0.004062:0.010894:0.009226:0.007578:0.009591:0.004513:0.004474:0.010625:0.009600
SV-A at progression:@0.525417:0.223643:0.681176:0.223643:0.681176:0.207254:0.525417:0.207254:0.009447:0.010422:0.005883:0.011727:0.004062:0.009236:0.006343:0.004062:0.010903:0.006072:0.010520:0.010595:0.006072:0.009600:0.007588:0.007588:0.004484:0.010520:0.010635
SV-B at baseline:@0.525417:0.243918:0.651826:0.243918:0.651826:0.227529:0.525417:0.227529:0.009447:0.010422:0.005883:0.010386:0.004062:0.009236:0.006343:0.004062:0.010903:0.009236:0.007588:0.009600:0.004522:0.004484:0.010635:0.009600
SV-B at progression:@0.525417:0.264194:0.679843:0.264194:0.679843:0.247804:0.525417:0.247804:0.009447:0.010422:0.005883:0.010386:0.004062:0.009236:0.006343:0.004062:0.010903:0.006076:0.010520:0.010595:0.006076:0.009600:0.007588:0.007588:0.004484:0.010520:0.010635
Supplementary Figure 8: Confirmation of presence of SVs in pre-amplified cfDNA. :@0.147059:0.302264:0.762110:0.302264:0.762110:0.284974:0.147059:0.284974:0.008554:0.009730:0.009600:0.009637:0.004856:0.007583:0.014810:0.007583:0.009861:0.005771:0.007900:0.007657:0.008180:0.004706:0.009488:0.005080:0.008797:0.009730:0.006761:0.007751:0.004706:0.008927:0.004445:0.004706:0.012381:0.009265:0.009955:0.004949:0.004949:0.006927:0.014810:0.007807:0.005752:0.005155:0.009264:0.009955:0.004706:0.009264:0.005678:0.004706:0.009525:0.006761:0.007751:0.006742:0.007583:0.009955:0.007433:0.007751:0.004706:0.009264:0.005678:0.004706:0.008666:0.012102:0.006574:0.004706:0.005080:0.009955:0.004706:0.009525:0.006761:0.007751:0.005902:0.007900:0.014717:0.009637:0.004781:0.005080:0.004949:0.005024:0.007956:0.009712:0.004706:0.007527:0.005678:0.013148:0.012233:0.012345:0.004445:0.003287
Detection of two :@0.763557:0.302264:0.885720:0.302264:0.885720:0.285595:0.763557:0.285595:0.013279:0.007471:0.005080:0.007452:0.007452:0.005267:0.004538:0.008871:0.009618:0.004819:0.008871:0.005080:0.004819:0.005267:0.011878:0.009039:0.003362
patient-specific SVs in cfDNA from blood from four prostate cancer patients at baseline and at progression :@0.147059:0.316816:0.885765:0.316816:0.885765:0.300148:0.147059:0.300148:0.009301:0.007209:0.005267:0.004538:0.007396:0.009320:0.005267:0.006163:0.006145:0.009413:0.007452:0.007359:0.004594:0.004650:0.004593:0.007359:0.003623:0.008274:0.012345:0.006275:0.003623:0.004594:0.009618:0.003623:0.007359:0.005080:0.012904:0.012607:0.012214:0.003623:0.005248:0.006089:0.008871:0.014437:0.003623:0.008927:0.004240:0.009226:0.009226:0.009320:0.003623:0.005248:0.006089:0.008871:0.014437:0.003623:0.004931:0.008853:0.009338:0.006387:0.003623:0.009058:0.006089:0.008965:0.006145:0.005360:0.007209:0.005080:0.007396:0.003623:0.007452:0.007433:0.009488:0.007359:0.007396:0.006387:0.003623:0.009301:0.007209:0.005267:0.004538:0.007396:0.009320:0.005267:0.006275:0.003623:0.007209:0.005267:0.003623:0.009095:0.007601:0.006443:0.007321:0.004296:0.004594:0.009488:0.007396:0.003623:0.007433:0.009488:0.009320:0.003623:0.007209:0.005267:0.003623:0.009058:0.006089:0.009039:0.008068:0.006089:0.007396:0.006163:0.006219:0.004538:0.008871:0.009618:0.003362
of disease with dPCR. Shown are VAFs. :@0.147059:0.332985:0.421692:0.332985:0.421692:0.316317:0.147059:0.316317:0.008871:0.005080:0.003362:0.009320:0.004594:0.006443:0.007599:0.007601:0.006443:0.007396:0.003362:0.012046:0.004314:0.005416:0.009376:0.003362:0.009320:0.009955:0.012009:0.011204:0.003679:0.003362:0.008031:0.009245:0.008890:0.012046:0.009618:0.003362:0.007433:0.006089:0.007396:0.003362:0.010291:0.012214:0.009226:0.006275:0.003679:0.003362
0:@0.174567:0.497830:0.180535:0.497830:0.180535:0.487944:0.174567:0.487944:0.005968
10:@0.168646:0.456585:0.180582:0.456585:0.180582:0.446699:0.168646:0.446699:0.005968:0.005968
100:@0.162733:0.418531:0.181641:0.418531:0.181641:0.408645:0.162733:0.408645:0.006302:0.006302:0.006302
VAF stock DNA (%) :@0.167112:0.493917:0.167112:0.415644:0.150332:0.415644:0.150332:0.493917:0.006982:-0.554339:0.000000:0.000000:0.000000:0.582650:-0.582650:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.657861
0:@0.185438:0.505925:0.191406:0.505925:0.191406:0.496039:0.185438:0.496039:0.005968
10:@0.266791:0.505925:0.278727:0.505925:0.278727:0.496039:0.266791:0.496039:0.005968:0.005968
100:@0.342906:0.505928:0.361813:0.505928:0.361813:0.496042:0.342906:0.496042:0.006302:0.006302:0.006302
VAF pre-amplified cfDNA (%) :@0.186654:0.516779:0.356261:0.516779:0.356261:0.504916:0.186654:0.504916:0.006996:0.008544:0.006799:0.002960:0.007944:0.004425:0.007385:0.004286:0.006729:0.011643:0.007944:0.003295:0.003267:0.003651:0.003651:0.006994:0.007874:0.002960:0.006254:0.004076:0.009298:0.009186:0.008544:0.002960:0.003965:0.011057:0.003965:0.002960
r  = 0.928:@0.310723:0.483887:0.355358:0.483887:0.355358:0.474001:0.310723:0.474001:0.003804:0.002685:0.002466:0.006934:0.002466:0.005968:0.002408:0.005968:0.005968:0.005968
s:@0.314527:0.485768:0.317213:0.485768:0.317213:0.480004:0.314527:0.480004:0.002686
Y = 0.72X + 0.82:@0.278065:0.493756:0.355358:0.493756:0.355358:0.483870:0.278065:0.483870:0.006294:0.002466:0.006934:0.002466:0.005968:0.002408:0.005968:0.005968:0.006643:0.002466:0.006934:0.002466:0.005968:0.002408:0.005968:0.005968
A:@0.151937:0.391098:0.160481:0.391098:0.160481:0.379235:0.151937:0.379235:0.008544
0:@0.424674:0.499585:0.430642:0.499585:0.430642:0.489699:0.424674:0.489699:0.005968
10:@0.418927:0.460873:0.430863:0.460873:0.430863:0.450987:0.418927:0.450987:0.005968:0.005968
100:@0.413192:0.424663:0.432099:0.424663:0.432099:0.414777:0.413192:0.414777:0.006302:0.006302:0.006302
VAF wildtype downstream :@0.403371:0.512376:0.403371:0.402383:0.386590:0.402383:0.386590:0.512376:0.006982:-0.292021:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.339685:-0.339685:0.000000:0.000000:0.000000:0.000000:0.379520:-0.379520:0.000000:0.000000:0.000000:0.412053:-0.412053:0.000000:0.000000:0.440324
 allele (%) :@0.420123:0.478041:0.420123:0.436708:0.403343:0.436708:0.403343:0.478041:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.058352
0:@0.435247:0.506165:0.441215:0.506165:0.441215:0.496279:0.435247:0.496279:0.005968
10:@0.514751:0.506091:0.526687:0.506091:0.526687:0.496205:0.514751:0.496205:0.005968:0.005968
100:@0.584721:0.506089:0.603628:0.506089:0.603628:0.496203:0.584721:0.496203:0.006302:0.006302:0.006302
VAF wildtype upstream allele (%) :@0.420633:0.516779:0.613903:0.516779:0.613903:0.504916:0.420633:0.504916:0.006994:0.008544:0.006799:0.002960:0.010275:0.003267:0.003295:0.007874:0.004747:0.006575:0.007944:0.006994:0.002960:0.007692:0.007944:0.005528:0.004621:0.004427:0.006994:0.006729:0.011643:0.002960:0.006729:0.003295:0.003295:0.006994:0.003295:0.006994:0.002960:0.003965:0.011057:0.003965:0.002960
r  = 0.996:@0.552272:0.484957:0.596908:0.484957:0.596908:0.475071:0.552272:0.475071:0.003804:0.002685:0.002466:0.006934:0.002466:0.005968:0.002408:0.005968:0.005968:0.005968
s:@0.556076:0.486839:0.558762:0.486839:0.558762:0.481075:0.556076:0.481075:0.002686
Y = 1.05X - 0.13:@0.522977:0.494826:0.596908:0.494826:0.596908:0.484941:0.522977:0.484941:0.006294:0.002466:0.006934:0.002466:0.005968:0.002408:0.005968:0.005968:0.006643:0.002466:0.003572:0.002466:0.005968:0.002408:0.005968:0.005968
B:@0.388196:0.391098:0.395763:0.391098:0.395763:0.379235:0.388196:0.379235:0.007567
0:@0.665235:0.500215:0.671203:0.500215:0.671203:0.490329:0.665235:0.490329:0.005968
10:@0.659314:0.457588:0.671250:0.457588:0.671250:0.447702:0.659314:0.447702:0.005968:0.005968
100:@0.653404:0.421171:0.672311:0.421171:0.672311:0.411285:0.653404:0.411285:0.006302:0.006302:0.006302
VAF Replicate 2 (%) :@0.655458:0.496017:0.655458:0.415534:0.638678:0.415534:0.638678:0.496017:0.006982:-0.063028:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.127732:-0.127732:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.169670
0:@0.676110:0.507569:0.682078:0.507569:0.682078:0.497684:0.676110:0.497684:0.005968
10:@0.757464:0.507569:0.769400:0.507569:0.769400:0.497684:0.757464:0.497684:0.005968:0.005968
100:@0.835903:0.507573:0.854810:0.507573:0.854810:0.497687:0.835903:0.497687:0.006302:0.006302:0.006302
VAF Replicate 1 (%) :@0.705318:0.516779:0.819165:0.516779:0.819165:0.504916:0.705318:0.504916:0.006996:0.008544:0.006799:0.002960:0.007511:0.006994:0.007944:0.003295:0.003267:0.006254:0.006729:0.004536:0.006994:0.002960:0.007162:0.002960:0.003965:0.011057:0.003965:0.002960
r  = 0.987:@0.801393:0.485533:0.846029:0.485533:0.846029:0.475647:0.801393:0.475647:0.003804:0.002685:0.002466:0.006934:0.002466:0.005968:0.002408:0.005968:0.005968:0.005968
s:@0.805197:0.487414:0.807883:0.487414:0.807883:0.481651:0.805197:0.481651:0.002686
Y = 0.918X + 0.17:@0.762767:0.495402:0.846029:0.495402:0.846029:0.485517:0.762767:0.485517:0.006294:0.002466:0.006934:0.002466:0.005968:0.002408:0.005968:0.005968:0.005968:0.006643:0.002466:0.006934:0.002466:0.005968:0.002408:0.005968:0.005968
C:@0.640281:0.393061:0.648378:0.393061:0.648378:0.381199:0.640281:0.381199:0.008097
Supplementary Figure 9: Technical aspects of dPCR. (A):@0.147059:0.545320:0.562139:0.545320:0.562139:0.528029:0.147059:0.528029:0.008554:0.009730:0.009600:0.009637:0.004856:0.007583:0.014810:0.007583:0.009861:0.005771:0.007900:0.007657:0.008180:0.004538:0.009488:0.005080:0.008797:0.009730:0.006761:0.007751:0.004538:0.008927:0.004445:0.004538:0.009077:0.007956:0.007433:0.009637:0.009955:0.005153:0.007695:0.008143:0.004781:0.004538:0.008068:0.006574:0.009878:0.007956:0.007639:0.005939:0.006574:0.004538:0.009264:0.005678:0.004538:0.009712:0.010571:0.012084:0.011579:0.004445:0.004538:0.006238:0.012345:0.006238
 Comparison of VAF in pre-amplified cfDNA :@0.562171:0.545320:0.885743:0.545320:0.885743:0.528651:0.562171:0.528651:0.004650:0.012270:0.008871:0.014138:0.009301:0.007433:0.006387:0.004594:0.006442:0.008871:0.009618:0.004650:0.008871:0.005080:0.004650:0.010291:0.012214:0.009226:0.004650:0.004594:0.009618:0.004650:0.009060:0.006089:0.007396:0.006163:0.007433:0.014138:0.009135:0.004296:0.004594:0.004650:0.004594:0.007452:0.009320:0.004650:0.007359:0.005080:0.012905:0.012607:0.012214:0.003362
and VAF in stock (non-pre-amplified) cfDNA. :@0.147059:0.559872:0.469116:0.559872:0.469116:0.543203:0.147059:0.543203:0.007433:0.009488:0.009320:0.003324:0.010291:0.012214:0.009226:0.003324:0.004594:0.009618:0.003324:0.006145:0.005080:0.009226:0.007172:0.008610:0.003324:0.005678:0.009488:0.008871:0.009618:0.006163:0.009058:0.006089:0.007396:0.006163:0.007433:0.014138:0.009133:0.004296:0.004594:0.004650:0.004594:0.007452:0.009320:0.005678:0.003324:0.007359:0.005080:0.012905:0.012607:0.012214:0.003679:0.003362
(B):@0.469049:0.559872:0.492787:0.559872:0.492787:0.542581:0.469049:0.542581:0.006238:0.011262:0.006238
 Comparison of VAF based on up- and downstream wild :@0.492787:0.559872:0.885754:0.559872:0.885754:0.543203:0.492787:0.543203:0.003324:0.012269:0.008871:0.014138:0.009301:0.007433:0.006387:0.004594:0.006443:0.008871:0.009618:0.003324:0.008871:0.005080:0.003324:0.010291:0.012214:0.009226:0.003324:0.009095:0.007601:0.006442:0.007452:0.009320:0.003324:0.008871:0.009618:0.003324:0.009058:0.009226:0.006163:0.003324:0.007433:0.009488:0.009320:0.003324:0.009264:0.008890:0.012046:0.009506:0.006145:0.005267:0.006089:0.007601:0.007433:0.014437:0.003324:0.012046:0.004706:0.004240:0.009320:0.003362
type alleles. :@0.147059:0.574424:0.230795:0.574424:0.230795:0.557755:0.147059:0.557755:0.005267:0.007956:0.009413:0.007396:0.005089:0.007695:0.004406:0.004241:0.007321:0.004240:0.007396:0.006275:0.003679:0.003362
(C):@0.232521:0.574424:0.257080:0.574424:0.257080:0.557133:0.232521:0.557133:0.006238:0.012084:0.006238
 Comparison of VAF in technical replicates of dPCR of pre-amplified cfDNA samples of :@0.257080:0.574424:0.885715:0.574424:0.885715:0.557755:0.257080:0.557755:0.005089:0.012270:0.008871:0.014138:0.009301:0.007433:0.006387:0.004594:0.006443:0.008871:0.009618:0.005089:0.008869:0.005080:0.005089:0.010291:0.012214:0.009226:0.005089:0.004594:0.009618:0.005089:0.005080:0.007452:0.007172:0.009376:0.009618:0.004538:0.007452:0.007693:0.004296:0.005089:0.006089:0.007471:0.009133:0.004296:0.004538:0.007452:0.007209:0.005080:0.007396:0.006275:0.005089:0.008871:0.005080:0.005089:0.009320:0.009955:0.012009:0.010944:0.005087:0.008873:0.005080:0.005087:0.009058:0.006089:0.007396:0.006163:0.007433:0.014138:0.009133:0.004296:0.004594:0.004650:0.004594:0.007452:0.009320:0.005089:0.007359:0.005080:0.012905:0.012607:0.012214:0.005087:0.006499:0.007433:0.014138:0.009133:0.004240:0.007396:0.006275:0.005089:0.008873:0.005080:0.003362
Pros5 and Pros6. :@0.147059:0.588976:0.266289:0.588976:0.266289:0.572307:0.147059:0.572307:0.009749:0.006089:0.008965:0.006275:0.008535:0.003362:0.007433:0.009488:0.009320:0.003362:0.009749:0.006089:0.008965:0.006275:0.008535:0.003679:0.003362